Contact   |   Login

Pharmapex Group Takes Initiatives to Assist with PPE Shortages

Pharmapex has decades of experience in R&D, production and inspections for manufacturing customized and generic medical consumables, including but not limited to personal protective equipment (PPE) products. Our standardized testing labs and advanced automated and up-to-date production equipment allow us to offer a wide range of PPE products, something that can assist the general population and hospital personnel in effectively combatting coronavirus spread. We are just as meticulous about the specification, development and manufacturing of our PPE products as we are about the manufacturing of our high value capital medical equipment.

Apart from two facilities in mainland China and Malaysia, all of our manufacturing facilities for medical consumables are located in the United States. In order to ensure the highest and most consistent product quality, all of our products are manufactured in accordance to US FDA/CDC approvals and pass through rigorous screening in Pharmapex's state of the art internal manufacturing and quality control procedures.

FEATURED: Under the Coronavirus pandemic, US FDA and CDC have recently ruled that specific devices, which are approved by countries for occupational use according to their own country-specific standards and are evaluated using similar methods to those used by the NIOSH, are expected to provide the required protection against Coronavirus granted that the proper fit for these products is achieved. Under the above ruling, these products - although not fully compliant with the US standards - may be considered to be suitable alternatives to provide protection during the COVID-19 response when supplies are short.  

The restrictions on export and import to the United States, our commitments to companies that have been loyal customers for several years, and limitations on our residual manufacturing capacity, has pushed us at Pharmapex to take the initiative to leverage the FDA/CDC provision and formed a strategic partnership with other leading manufacturers across the world to better assist general public and affected areas with the ongoing shortages.  

As a result of this strategic partnership, we are currently producing a comprehensive range of supplementary PPE products in substantial quantities and approved qualities. We take pride in supplying these products to the United Nations and affected regions at the most affordable pricing and in many cases at zero net margins.  

If you are associated with a non-profit organization, governmental agency, or a company in an affected region by Coronavirus, please contact us to discuss our range of possibilities and how we can be of assistance to you and your community.

Quick Contact

Presentation Download:
To download a generic presentation for our comprehensive range of PPE products, click here.

Latest Newsletters:

Press Releases and Latest News:
PND releases a 200+ page catalog for Vitanova Signature™
Pharmapex's Nutrition Department releases an extensive 2016 catalog for dietary supplements.

Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.

FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© , Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.